Citrate salts for preventing and treating calcium containing kidney stones in adults

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 10, 2015, Pages

  Phillips, Rebecca ^a   Hanchanale, Vishwanath S ^b   Myatt, Andy ^a   Somani, Bhaskar ^c   Nabi, Ghulam ^d   Biyani, C Shekhar ^b  

^a CASTLE HILL HOSPITAL   (United Kingdom)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^c UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^d UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXYLIC ACID SALT; CITRATE POTASSIUM; CITRATE POTASSIUM SODIUM; PLACEBO; POTASSIUM MAGNESIUM CITRATE; UNCLASSIFIED DRUG; CALCIUM OXALATE; CALCIUM PHOSPHATE; CITRIC ACID; DRUG COMBINATION; MAGNESIUM DERIVATIVE; POTASSIUM DERIVATIVE; POTASSIUM-MAGNESIUM CITRATE;

BLOATING; CALCIUM CONTAINING KIDNEY STONE; DRUG EFFICACY; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HUMAN; NAUSEA; NEPHROLITHIASIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; STOMACH PAIN; STONE FORMATION; SYSTEMATIC REVIEW; TREATMENT DURATION; ADULT; CHEMISTRY; DRUG COMBINATION; KIDNEY CALCULI; META ANALYSIS; RECURRENT DISEASE; SECONDARY PREVENTION; URINE;

ADULT; CALCIUM OXALATE; CALCIUM PHOSPHATES; CITRATES; DRUG COMBINATIONS; HUMANS; KIDNEY CALCULI; MAGNESIUM COMPOUNDS; POTASSIUM COMPOUNDS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; SECONDARY PREVENTION;

EID: 84979859148     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD010057.pub2     Document Type: Review

References (85)

1. Barcelo P, Wuhl O, Servitge E, Rousaud A, Pak CY. Randomized double-blind study of potassium citrate in idiopathic hypocitraturic calcium nephrolithiasis. Journal of Urology 1993;150(6):1761-4. [MEDLINE: 8230497]
2. Cicerello E, Merlo F, Gambaro G, Maccatrozzo L, Fandella A, Baggio B, et al. Effect of alkaline citrate therapy on clearance of residual renal stone fragments after extracorporeal shock wave lithotripsy in sterile calcium and infection nephrolithiasis patients. Journal of Urology 1994;151(1):5-9. [MEDLINE: 8254832]
3. Ettinger B, Pak CY, Citron JT, Thomas C, Adams-Huet B, Vangessel A. Potassium-Magnesium citrate is an effective prophylaxis against recurrent calcium oxalate nephrolithiasis. Journal of Urology 1997;158(6):2069-73. [MEDLINE: 9366314]
4. Hofbauer J, Hobarth K, Szabo N, Marberger M. Alkali citrate prophylaxis in idiopathic recurrent calcium oxalate urolithiasis--a prospective randomized study. British Journal of Urology 1994;73(4):362-5. [MEDLINE: 8199822]
5. Jimenez Verdejo A, Arrabal Martin M, Mijan Ortiz JL, Hita Rosino E, Palao Yago F, Zuluaga Gomez A. Effect of potassium citrate in the prophylaxis of urinary lithiasis [Efecto del citrato potasico en la profilaxis de la litiasis urinaria]. Archivos Espanoles de Urologia 2001;54(9):1036-46. [MEDLINE: 11789361]
6. Lojanapiwat B, Tanthanuch M, Pripathanont C, Ratchanon S, Srinualnad S, Taweemonkongsap T, et al. Alkaline citrate reduces stone recurrence and regrowth after shockwave lithotripsy and percutaneous nephrolithotomy. International Brazilian Journal of Urology 2011;37(5):611-6. [MEDLINE: 22099273]
7. Lojanapiwat B, Tanthanuch M, Pripathanont C, Ratchanon S, Srinualnad S, Taweemonkongsap T, et al. Effect of alkaline citrate on stone recurrence and regrowth after shock wave lithotripsy and percutaneous nephrolithotomy in calcium urolithiasis: A randomised controlled trial [abstract]. Archivio Italiano di Urologia e Andrologia 2009;81(3):141. [EMBASE: 70036858]
8. Soygur T, Akbay A, Kupeli S. Effect of potassium citrate therapy on stone recurrence and residual fragments after shockwave lithotripsy in lower caliceal calcium oxalate urolithiasis: a randomized controlled trial. Journal of Endourology 2002;16(3):149-52. [MEDLINE: 12028622]
9. Allie-Hamdulay S, Rodgers AL. Prophylactic and therapeutic properties of a sodium citrate preparation in the management of calcium oxalate urolithiasis: randomized, placebo-controlled trial. Urological Research 2005;33(2):116-24. [MEDLINE: 15871014]
10. Aras B, Kalfazade N, Tugcu V, Kemahli E, Ozbay B, Polat H, et al. Can lemon juice be an alternative to potassium citrate in the treatment of urinary calcium stones in patients with hypocitraturia? A prospective randomized study. Urological Research 2008;36(6):313-7. [MEDLINE: 18946667]
11. Brardi S, Imperiali P, Cevenini G, Verdacchi T, Ponchietti R. Effects of the association of potassium citrate and agropyrum repens in renal stone treatment: results of a prospective randomized comparison with potassium citrate. Archivio Italiano di Urologia, Andrologia 2012;84(2):61-7. [MEDLINE: 22908773]
12. El-Gamal O, El-Bendary M, Ragab M, Rasheed M. Role of combined use of potassium citrate and tamsulosin in the management of uric acid distal ureteral calculi. Urological Research 2012;40(3):219-24. [MEDLINE: 21858663]
13. Elbenday M, Elgamal O, Elbadry A, Attia M. Role of combined use of potassium citrate and tamsulosin in the management of uric acid distal ureteral calculi [abstract no: 1317]. Journal of Urology 2010;183(4 Suppl 1):e509. [EMBASE: 70144990]
14. Ettinger B. Recurrent nephrolithiasis: natural history and effect of phosphate therapy. A double-blind controlled study. American Journal of Medicine 1976;61(2):200-6. [MEDLINE: 782240]
15. Fernandez Rodrigues A, Arrabal Martin M, Garcia Ruiz MJ, De Haro Munoz T, Zuluaga Gomez A. Effect of thiazide therapy in the prophylaxis of calcium lithiasis [Efecto de las tiazidas en la profilaxis de la litiasis calcica]. Archivos Espanoles de Urologia 2001;54(9):1047-54. [MEDLINE: 11789362]
16. Fernandez-Rodriguez A, Arrabal-Martin M, Garcia-Ruiz MJ, Arrabal-Polo MA, Pichardo-Pichardo S, Zuluaga-Gomez A. The role of thiazides in the prophylaxis of recurrent calcium lithiasis [Papel de las tiazidas en la profilaxis de la litiasis calcica recidivante]. Actas Urologicas Espanolas 2006;30(3):305-9. [MEDLINE: 16749588]
17. Gao J, Shen Y, Sun N, Jia LQ, Pan YS, Sun Q. Therapeutic effects of potassium sodium hydrogen citrate on melamine-induced urinary calculi in China. Chinese Medical Journal 2010;123(9):1112-6. [MEDLINE: 20529547]
18. He HC, Zhong WD, Xie KJ, Dai QS, Zeng GQ, Wei H, et al. Effects of potassium citrate delayed preparation in urine PH and citric acid content. Chung-Hua i Hsueh Tsa Chih [Chinese Medical Journal] 2004;84(21):1825-6. [MEDLINE: 15631783]
19. Heguilen RM, Bellusci AD, Bernasconi AR. Differential impact of potassium citrate and hydrochlorothiazide in hypercalciuric patients [abstract no: TH-PO877]. Journal of the American Society of Nephrology 2005;16:311A.
20. Jaipakdee S, Prasongwatana V, Premgamone A, Reungjui S, Tosukhowong P, Tungsanga K, et al. The effects of potassium and magnesium supplementations on urinary risk factors of renal stone patients. Journal of the Medical Association of Thailand 2004;87(3):255-63. [MEDLINE: 15117041]
21. Kato Y, Yamaguchi S, Yachiku S, Nakazono S, Hori J, Wada N, et al. Changes in urinary parameters after oral administration of potassium-sodium citrate and magnesium oxide to prevent urolithiasis. Urology 2004;63(1):7-11. [MEDLINE: 14751336]
22. Khanniazi MK, Khanam A, Naqvi SA, Sheikh MA. Study of potassium citrate treatment of crystalluric nephrolithiasis. Biomedical Pharmacotherapy 1993;47(1):25-8. [MEDLINE: 8329662]
23. Koff SG, Paquette EL, Cullen J, Gancarczyk KK, Tucciarone PR, Schenkman NS. Comparison between lemonade and potassium citrate and impact on urine pH and 24-hour urine parameters in patients with kidney stone formation. Urology 2007;69(6):1013-6. [MEDLINE: 17572176]
24. Lee YH, Huang WC, Tsai JY, Huang JK. The efficacy of potassium citrate based medical prophylaxis for preventing upper urinary tract calculi: a midterm followup study. Journal of Urology 1999;161(5):1453-7. [MEDLINE: 10210371]
25. Ruggenenti P. A prospective, randomised, open blind endpoint (probe) trial to assess the possibility to prevent stone recurrence by lemon juice supplementation in patients with recurrent calcium oxalate nephrolithiasis (LIMONE Study). www.clinicaltrials.gov/show/NCT01217372 (accessed 29 July 2015).
26. Mechlin C, Kalorin C, Asplin J, White M. Splenda improves tolerance of oral potassium citrate supplementation for prevention of stone formation: results of a randomized double-blind trial. Journal of Endourology 2011;25(9):1541-5. [MEDLINE: 21815827]
27. Mechlin CW, Kalorin C, Asplin J, White MD. Splenda improves tolerance of oral potassium citrate supplementation: results of a randomized double blind trial [abstract no: PS25-8]. Journal of Endourology 2010;24(Suppl 1):A197. [EMBASE: 70295603]
28. Mortensen JT, Schultz A, Ostergaard AH. Thiazides in the prophylactic treatment of recurrent idiopathic kidney stones. International Urology & Nephrology 1986;18(3):265-9. [MEDLINE: 3533825]
29. Pak CY, Koenig K, Khan R, Haynes S, Padalino P. Physicochemical action of potassium-magnesium citrate in nephrolithiasis. Journal of Bone & Mineral Research 1992;7(3):281-5. [MEDLINE: 1585829]
30. Pearle MS. Effect of potassium citrate therapy on stone recurrence and residual fragments after shockwave lithotripsy in lower caliceal calcium oxalate urolithiasis: a randomized controlled trial. International Brazilian Journal of Urology 2002;28(6):570-1. [MEDLINE: 15748408]
31. Pinheiro VB, Baxmann AC, Tiselius HG, Heilberg IP. The effect of sodium bicarbonate upon urinary citrate excretion in calcium stone formers. Urology 2013;82(1):33-7. [MEDLINE: 23602798]
32. Premgamone A, Sriboonlue P, Disatapornjaroen W, Maskasem S, Sinsupan N, Apinives C. A long-term study on the efficacy of a herbal plant, Orthosiphon grandiflorus, and sodium potassium citrate in renal calculi treatment. Southeast Asian Journal of Tropical Medicine & Public Health 2001;32(3):654-60. [MEDLINE: 11944733]
33. Preminger GM, Sakhaee K, Pak CY. Alkali action on the urinary crystallization of calcium salts: contrasting responses to sodium citrate and potassium citrate. Journal of Urology 1988;139(2):240-2. [MEDLINE: 3339718]
34. Sakhaee K, Nicar M, Hill K, Pak CY. Contrasting effects of potassium citrate and sodium citrate therapies on urinary chemistries and crystallization of stone-forming salts. Kidney International 1983;24(3):348-52. [MEDLINE: 6645208]
35. Sakhaee K, Poindexter JR, Griffith CS, Pak CY. Stone forming risk of calcium citrate supplementation in healthy postmenopausal women. Journal of Urology 2004;172(3):958-61. [MEDLINE: 15311008]
36. Sarica K, Erturhan S, Yurtseven C, Yagci F. Effect of potassium citrate therapy on stone recurrence and regrowth after extracorporeal shockwave lithotripsy in children. Journal of Endourology 2006;20(11):875-9. [MEDLINE: 17144854]
37. Schell-Feith EA, Moerdijk A, van Zwieten PH, Zonderland HM, Holscher HC, Kist-van Holthe J, et al. Does citrate prevent nephrocalcinosis in preterm neonates?. Pediatric Nephrology 2006;21(12):1830-6. [MEDLINE: 17039333]
38. See M, Chua M, Luna S. A prospective 6-weeks randomized controlled trial to evaluate the efficacy and safety of sodium bicarbonate, citric acid, sodium citrate, and tartaric acid compound compared to potassium citrate in the treatment of renal stones [abstract no: 2259]. Journal of Urology 2012;187(4 Suppl 1):e911-2. [EMBASE: 70721953]
39. See MC, Chua ME, Luna S. A prospective 6-week randomized controlled trial to evaluate the efficacy and safety of NA bicarbonate, citric acid, NA citrate, and tartaric acid coumpound drug compared to potassium citrate in the dissolution of renal stones [abstract]. Journal of Endourology 2012;26(Suppl 1):A8. [EMBASE: 70875588]
40. Singh RG, Behura SK, Kumar R. Litholytic property of Kulattha (Dolichous biflorus) vs potassium citrate in renal calculus disease: a comparative study. Journal of the Association of Physicians of India 2010;58:286-9. [MEDLINE: 21117346]
41. Singh I, Bishnoi I, Agarwal V, Bhatt S. Prospective randomized clinical trial comparing phytotherapy with potassium citrate in management of minimal burden (<8 mm) nephrolithiasis. Urology Annals 2011;3(2):75-81. [MEDLINE: 21747596]
42. Singh RG, Singh TB, Kumar R, Dwivedi US, Moorthy KN, Kumar N. A comparative pilot study of litholytic properties of celosia argental (Sitivaraka) versus potassium citrate in renal calculus disease. Journal of Alternative & Complementary Medicine 2012;18(5):427-8. [MEDLINE: 22537564]
43. Tosukhowong P, Yachantha C, Sasivongsbhakdi T, Ratchanon S, Chaisawasdi S, Boonla C, et al. Citraturic, alkalinizing and antioxidative effects of limeade-based regimen in nephrolithiasis patients. Urological Research 2008;36(3-4):149-55. [MEDLINE: 18560820]
44. Zerwekh JE, Odvina CV, Wuermser LA, Pak CY. Reduction of renal stone risk by potassium-magnesium citrate during 5 weeks of bed rest. Journal of Urology 2007;177(6):2179-84. [MEDLINE: 17509313]
45. Krishna RS, Shaik AB, Bokkisam S. Effect of potassium magnesium citrate and vitamin B-6 prophylaxis for recurrent and multiple calcium oxalate and phosphate urolithiasis. Korean Journal of Urology 2014;55(6):411-6. [MEDLINE: 24955227]
46. Maalouf NM. Pharmacological therapy for calcium phosphate urolithiasis. clinicaltrials gov/ct2/show/NCT01754779 (accessed 29 July 2015).
47. Fan J, Schwille PO, Schmiedl A, Fink E, Manoharan M. Calcium oxalate crystallization in undiluted postprandial urine of healthy male volunteers as influenced by citrate. Arzneimittel-Forschung 2001;51(10):848-57. [MEDLINE: 11715639]
48. Fink HA, Wilt TJ, Eidman KE, Garimella PS, MacDonald R, Rutks IR, et al. Recurrent nephrolithiasis in adults: comparative effectiveness of preventive medical strategies. Comparative Effectiveness Review No. 61. AHRQ Publication No. 12-EHC049-EF. 2012. effectivehealthcare.ahrq.gov/ehc/products/274/1035/kidney-stones-prevention-report-130517.pdf (accessed 26 August 2015).
49. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60. [MEDLINE: 12958120]
50. Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
51. Ito H, Suzuki F, Yamaguchi K, Nishikawa Y, Kotake T. Reduction of urinary oxalate by combined calcium and citrate administration without increase in urinary calcium oxalate stone formers. Clinical Nephrology 1992;37(1):14-8. [MEDLINE: 1541059]
52. Kissin B, Locks MO. Urinary citrates in calcium urolithiasis. Proceedings of the Society for Experimental Biology & Medicine 1941;46:216-8.
53. Kok DJ, Papapoulos SE, Bijvoet OL. Excessive crystal agglomeration with low citrate excretion in recurrent stone-formers. Lancet 1986;1(8489):1056-8. [MEDLINE: 2871335]
54. Levine BS, Rodman JS, Wienerman S, Bockman RS, Lane JM, Chapman DS. Effect of calcium citrate supplementation on urinary calcium oxalate saturation in female stone formers: implications for prevention of osteoporosis. American Journal of Clinical Nutrition 1994;60(4):592-6. [MEDLINE: 8092096]
55. Levy FL, Adams-Huet B, Pak CY. Ambulatory evaluation of nephrolithiasis: an update of a 1980 protocol. American Journal of Medicine 1995;98(1):50-9. [MEDLINE: 7825619]
56. Magaret SP, Yair L. Urinary lithiasis: diagnosis and medical management. In: Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA editor(s). Campbell's Urology. 9th Edition. Vol. 4, Philadelphia: Saunders, 2007:1363-92.
57. Mattle D, Hess B. Preventive treatment of nephrolithiasis with alkali citrate--a critical review. Urological Research 2005;33(2):73-9. [MEDLINE: 15875173]
58. Meyer JL, Smith LH. Growth of calcium oxalate crystals. II. Inhibition by natural urinary crystal growth inhibitors. Investigative Urology 1975;13(1):36-9. [MEDLINE: 166960]
59. Miller NL, Lingeman JE. Management of kidney stones. BMJ 2007;334(7591):468-72. [MEDLINE: 17332586]
60. Nicar MJ, Skurla C, Sakhaee K, Pak CY. Low urinary citrate excretion in nephrolithiasis. Urology 1983;21(1):8-14. [MEDLINE: 6823713]
61. Nowfar S, Palazzi-Churas K, Chang DC, Sur RL. The relationship of obesity and gender prevalence changes in United States inpatient nephrolithiasis. Urology 2011;78(5):1029-33. [MEDLINE: 21676441]
62. Pak CY. Citrate and renal calculi: new insights and future directions. American Journal of Kidney Diseases 1991;17(4):420-5. [MEDLINE: 2008910]
63. Pak CY. Citrate and renal calculi: an update. Mineral & Electrolyte Metabolism 1994;20(6):371-7. [MEDLINE: 7783699]
64. Pak CY. Kidney stones. Lancet 1998;351(9118):1797-801. [MEDLINE: 9635968]
65. Pak CY, Heller HJ, Pearle MS, Odvina CV, Poindexter JR, Peterson RD. Prevention of stone formation and bone loss in absorptive hypercalciuria by combined dietary and pharmacological interventions. Journal of Urology 2003;169(2):465-9. [MEDLINE: 12544288]
66. Parks JH, Coe FL. The financial effects of kidney stone prevention. Kidney International 1996;50(5):1706-12. [MEDLINE: 8914040]
67. Pearle MS, Roehrborn CG, Pak CY. Meta-analysis of randomised trials for medical prevention of calcium oxalate nephrolithiasis. Journal of Endourology 1999;13(9):679-85. [MEDLINE: 10608521]
68. Ratan SK, Bhatnagar V, Mitra DK, Basu N, Malhotra LK. Urinary citrate excretion in idiopathic nephrolithiasis. Indian Pediatrics 2002;39(9):819-25. [MEDLINE: 12368525]
69. Sarada B, Satyanarayana U. Urinary composition in men and women and the risk of urolithiasis. Clinical Biochemistry 1991;24(6):487-90. [MEDLINE: 1773489]
70. Scales CD Jr, Curtis LH, Norris RD, Springhart WP, Sur RL, Schulman KA, et al. Changing gender prevalence of stone disease. Journal of Urology 2007;177(3):979-82. [MEDLINE: 17296391]
71. Scales CD Jr, Smith AC, Hanley JM, Saigal CS, Urologic Diseases in America Project. Prevalence of kidney stones in the United States. European Urology 2012;62(1):160-5. [MEDLINE: 22498635]
72. Schulz KF, Altman DG, Moher D, CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340:c332. [MEDLINE: 20332509]
73. Schwille PO, Schmiedl A, Herrmann U, Schwille R, Fink E, Manoharan M. Acute oral calcium-sodium citrate load in healthy males. Effects on acid-base and mineral metabolism, oxalate and other risk factors of stone formation in urine. Methods & Findings in Experimental & Clinical Pharmacology 1997;19(6):417-27. [MEDLINE: 9385591]
74. Spivacow FR, Negri AL, del Valle EE, Calviño I, Zanchetta JR. Clinical and metabolic risk factor evaluation in young adults with kidney stones. International Urology & Nephrology 2010;42(2):471-5. [MEDLINE: 20399488]
75. Stamatelou KK, Francis ME, Jones CA, Nyberg LM, Curhan GC. Time trends in reported prevalence of kidney stones in the United States: 1976-1994. Kidney International 2003;63(5):1817-23. [MEDLINE: 12675858]
76. Strauss AL, Coe FL, Deutsch L, Parks JH. Factors that predict relapse of calcium nephrolithiasis during treatment: a prospective study. American Journal of Medicine 1982;72(1):17-24. [MEDLINE: 7058820]
77. Sutherland JW, Parks JH, Coe FL. Recurrence after a single renal stone in a community practice. Mineral & Electrolyte Metabolism 1985;11(4):267-9. [MEDLINE: 403360]
78. Tiselius HG, Berg C, Fornander AM, Nilsson MA. Effects of citrate on the different phases of calcium oxalate crystallization. Scanning Microscopy 1993;7(1):381-9. [MEDLINE: 8316807]
79. Trinchieri A, Boccafoschi C, Chisena S, De Angelis M, Seveso M. Study of the diuretic efficacy and tolerability of therapy with Rocchetta mineral water in patients with recurrent calcium kidney stones [Studio sulla tollerabilita e l'efficacia diuretica della idropinoterapia con acqua oligominerale Rocchetta in pazienti con nefrolitiasi calcica recidivante]. Archivio Italiano di Urologia, Andrologia 1999;71(2):121-4. [MEDLINE: 10408129]
80. Türk C, Knoll T, Petrik A, Sarica K, Skolarikos A, Straub M, et al. Guidelines on urolithiasis. European Association of Urology. 2014. uroweb.org/wp-content/uploads/22-Urolithiasis_LR.pdf (accessed 26 August 2015).
81. Uribarri J, Oh MS, Carroll HJ. The first kidney stone. Annals of Internal Medicine 1989;111(12):1006-9. [MEDLINE: 2688503]
82. Weisinger JR, Bellori E. Experiencia Latino Americana em Liti ase Renal Venezuela. In: Schor N, Pfeferman Heilberg I editor(s). Calculose Renal. Fisiopatologia, Diagnostico. Sao Paulo: Tratamiento, 1995:354-9.
83. Whalley NA, Meyers AM, Martins M, Margolius LP. Long-term effects of potassium citrate therapy on the formation of new stones in groups of recurrent stone formers with hypocitraturia. British Journal of Urology 1996;78(1):10-4. [MEDLINE: 8795392]
84. Zuckerman JM, Assimos DG. Hypocitraturia: pathophysiology and medical management. Reviews in Urology 2009;11(3):134-44. [MEDLINE: 19918339]
85. Hanchanale VS, Phillips R, Myatt A, Somani B, Nabi G, Biyani CS. Citrate salts for preventing and treating kidney stones. Cochrane Database of Systematic Reviews 2012, Issue 9. [DOI: 10.1002/14651858.CD010057]